Breast cancer claims the lives of approximately 670,000 individuals each year. In 2022, breast cancer was reported as the most prevalent cancer among women in 157 out of 185 countries, according to data from the World Health Organization (WHO). Over 2 million women are diagnosed with breast cancer annually, underscoring the importance of early detection and the development of targeted treatments for this deadly disease. The US Food and Drug Administration (FDA) has approved Kisqali, also known as ribociclib, for the treatment of early-stage breast cancer. This drug is to be used in combination with hormone therapy and offers a potential solution for patients concerned about cancer recurrence. Kisqali works as a selective cyclin-dependent kinase inhibitor, hindering the growth and division of cancer cells by targeting specific proteins. It will be administered in the form of an oral pill, taken for three weeks followed by a one-week break, and continued for a period of three years. The recommended daily dose is 400 mg, which can be taken with or without food.Kisqali Side Effects: Common side effects of Kisqali medication include low white blood cell count or neutropenia. Neutropenia arises when there is a decrease in neutrophil levels in the blood, which are crucial for combating infections in the body. Additionally, Kisqali may lead to liver-related problems and interstitial lung disease/pneumonitis. Recognizing Early Signs of Breast Cancer that Should Not Be Overlooked